Masimo (MASI) Projected to Post Quarterly Earnings on Thursday

Masimo (NASDAQ:MASI) is anticipated to release its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Masimo to post earnings of $1.41 per share and revenue of $407.9730 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Masimo Stock Performance

MASI stock opened at $175.61 on Thursday. The firm has a 50 day moving average of $137.72 and a two-hundred day moving average of $142.84. Masimo has a 12 month low of $125.94 and a 12 month high of $194.88. The company has a market capitalization of $9.43 billion, a price-to-earnings ratio of -16.66, a P/E/G ratio of 1.77 and a beta of 1.26. The company has a quick ratio of 1.92, a current ratio of 2.84 and a debt-to-equity ratio of 0.69.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MASI. Naya Capital Management UK Ltd. bought a new stake in shares of Masimo in the fourth quarter valued at about $202,984,000. State Street Corp increased its position in shares of Masimo by 0.7% during the second quarter. State Street Corp now owns 1,486,394 shares of the medical equipment provider’s stock valued at $250,041,000 after purchasing an additional 10,403 shares during the period. Alyeska Investment Group L.P. increased its position in shares of Masimo by 21.7% during the third quarter. Alyeska Investment Group L.P. now owns 1,381,085 shares of the medical equipment provider’s stock valued at $203,779,000 after purchasing an additional 246,595 shares during the period. Durable Capital Partners LP raised its stake in shares of Masimo by 3.4% in the second quarter. Durable Capital Partners LP now owns 1,163,898 shares of the medical equipment provider’s stock valued at $195,791,000 after purchasing an additional 38,279 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in Masimo by 3,416.5% in the fourth quarter. AQR Capital Management LLC now owns 1,091,326 shares of the medical equipment provider’s stock worth $141,938,000 after purchasing an additional 1,060,292 shares during the period. Institutional investors own 85.96% of the company’s stock.

Masimo News Roundup

Here are the key news stories impacting Masimo this week:

• Positive Sentiment: Danaher agreed to acquire Masimo for $180 per share in cash (~$9.9B), giving investors a clear near‑term valuation anchor and a sizeable premium to pre‑deal levels. Danaher To Acquire Masimo Corporation
• Positive Sentiment: Market reaction: MASI surged on the deal (investors captured roughly a ~34% jump when the news broke), and the stock is trading at elevated volume as merger‑arbitrage activity prices in deal close probability and timing. Masimo shares jump 34% after Danaher agrees to buy the company
• Positive Sentiment: Analyst take on the deal: coverage notes Danaher’s purchase presents solid long‑term financial upside and conservative growth assumptions under new ownership, supporting the strategic rationale for the acquisition. Danaher’s Masimo Acquisition: Solid Financials, Conservative Growth Projections
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating but trimmed its price target to $180 (from $190), effectively aligning its target with the cash offer and signaling limited upside beyond the deal price. Wells Fargo rating / Benzinga
• Neutral Sentiment: Founder/management commentary: founder Joe Kiani and company coverage pieces are framing the sale and future under Danaher; such commentary helps set expectations for integration and standalone operations post‑close. Masimo Founder Joe Kiani On The Healthtech Company’s $10 Billion Acquisition
• Negative Sentiment: Multiple law firms have launched investigations and shareholder groups are probing whether Masimo’s board obtained a fair price, creating potential legal/transactional risk that could delay or alter the deal terms. Shareholder Alert: M&A Class Action Firm Investigating Masimo

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Wells Fargo & Company restated an “equal weight” rating and set a $180.00 target price (down from $190.00) on shares of Masimo in a report on Wednesday. Stifel Nicolaus set a $180.00 price objective on Masimo in a research note on Tuesday. Piper Sandler lowered Masimo from an “overweight” rating to a “hold” rating and set a $180.00 target price for the company. in a report on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Monday, December 1st. Finally, Zacks Research lowered shares of Masimo from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $181.17.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.